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‘How to shift from population-based data
toward personal health care?’
According to the SEERCancer Statistics Review, between 1975
and 2005, the deaths from heart disease in the United States
declined from 37.8 to 26.6%, whereas over the same period
those from cancer increased from 19.2 to 22.8% (Ries et al,
2008). In the US alone, it is estimated that in 2008 a total
of 565,650 patients will have died from cancer, whereas
1,437,180 will have been newly diagnosed (Jemal et al, 2008).
Thus, despite undeniable advancements in early diagnostics
and progress in reducing morbidity through therapeutic
efforts, it appears that after spending billions of dollars on
oncology research since 1971, more than three decades later
the ‘war on cancer’ is still far from being won (http://
dtp.nci.nih.gov/timeline/noﬂash/milestones/M4_Nixon.htm).
Although pressure from patients, advocacy groups and
funding agencies is mounting, the conventional population-
based approach for therapeutic developments in clinics still
relies on passing a series of randomized controlled trials that
depend on enrollment of many patients in search for favorable
yet averaged outcome patterns that statistically document
safety and efﬁcacy. Research and development (R&D) of a new
therapeutic drug now takes 10–15 years at a cost in excess of
US$1.3 billion, with only 20% of marketed drugs producing
revenues that match or exceed their R&D costs (Pharmaceu-
ticalResearchandManufacturersofAmerica,2008).Fueledby
the comparably modest progress made so far in pursuing this
expensive conventional route, there has been much interest
lately in moving toward personalized or patient-speciﬁc
medicine. For oncology, for instance, ‘speciﬁc’ refers to
assessing not only tumor type, size, location, patient age and
many other parameters that are already used and that result in
the conventional grading and staging of the disease; rather, it
argues for incorporating also the molecular ﬁngerprint, or
signature, and associated growth kinetics of the patient’s
tumor when ﬁne-tuning treatment regimen on a case-by-case
basis (Roukos et al, 2007). As everyone’s tumor is distinct, to a
degree, the ‘one-size-ﬁts-all’ treatment strategy cannot work,
so the new paradigm.
Although few would argue against the rationale behind the
concept per se, what remains unclear, however, is how to
actually process personalized medicine when the costs on the
diagnostic side, such as that for advanced personalized
molecular screenings, cease to be the limiting factor due to a
wide range of ongoing biomedical engineering efforts (e.g.
Shendure et al, 2008). Next steps will involve having to
address as to how to design, run and evaluate clinical trials in
this new era, and how to administer personalized health care
in reality. That is, (1) following the new paradigm, the
averaged results derived from randomized clinical trials will
offer insufﬁcient if not even incorrect guidance on how to
approachaspeciﬁccase.Patientresponsestoaparticulardrug,
for instance, are known to fall into a more or less wide range
that deviates from the averaged behavior, a fact that is being
made chieﬂy responsible for why a particular drug works
better in some than in others. Although, in an effort to limit
adverse side effects for the patient population at large, toxicity
testing will likely have to continue to rely on a conventional
trial-based approach, efﬁcacy assessment will have to reﬂect
the new paradigm in one form or another. (2) An equally
signiﬁcant challenge looms on the day-to-day operations side
in clinics where at any point in time, multiple, slightly varied
treatment protocols will have to be designed, administered,
monitored and adjusted if need be. At the very least, that puts
considerable strains on the existing infrastructure. Also,
enrollment numbers will be small, in theory down to one
patient per modiﬁed regimen, with the obvious consequence
that clinical institutions will have to pool and exchange such
case-centricdataandexpertisesothatnewpatientscanbeneﬁt
from past experience. (3) Even if a compound survives the
elaborate evaluation processes in the current pharmaceutical
‘pipeline,’bythetimeitbecomesavailable,itlagsseveralyears
behind the pace of basic research that continued while the
drug was under development. Consequently, new data would
have become available that may point toward different, or
higher valued targets, or even question the rationale of the
initially chosen strategy altogether. Short of starting the
development process all over and facing the same dilemma
again in a few years, aworkﬂow has to be designed that allows
including new R&D insights, also from this new case-centric
medicine, into thedevelopmentprocess inaneffort to improve
the drug’s efﬁcacy at later stages in the pipeline—without
compromising patient safety and at acceptable costs for
industry.
This leads to a key question. As, at least in the early stages,
this necessary move toward personalized medicine ideally has
to build on available population data, how can we consolidate
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shift will likelycomewith a hefty price tag as it requires design
and development of massive data storage, mining and transfer
capabilities, efﬁciently linked through innovative web-based
workﬂows. It is here where systems biology (e.g. Coffey, 1998;
Ahn et al, 2006; Hornberg et al, 2006; Liu et al, 2006) or, more
precisely, computational systems medicine can make all the
difference. At the core of all this is the quest to gain insights
into the intricacies of nonlinear structure–function relation-
ships, across multiple resolutions, in space and time. Through
its quantitative strengths, systems biology already generates
invaluable fundamental insights into the organization, func-
tions and dysfunctions of biological networks (Kitano, 2002;
Chuang et al, 2007; Yildirim et al, 2007; Zhu et al, 2008). It has
also recently begun to tackle the critical issues of the
integration of biomedical data across scales and from diverse
sources (Deisboeck et al, 2009). However, the ﬁeld is still in its
infancy and has yet to deliver applied solutions for the life
sciences in general and medicine in particular.
Two scenarios
To exemplify how these approaches can eventually be
integrated into more conventional workﬂows, and why this
should constitute ‘added value’, I brieﬂy introduce two
scenarios inspired from our own works on computational
cancer biology.
(A) Incorporating a comprehensive data set from a patient
(e.g. molecular biomarker, histology, and imaging data) into
anadvancedcomputationalmodelingplatform(e.g.Wangand
Deisboeck, 2008; Zhang et al, 2009) and then training the
model on this patient’s data as they come forward, will
necessarily yield a more accurate description of the speciﬁc
kinetics of disease progression or treatment outcome; hence,
this approach should provide a higher predictive power than
that achieved with pooled data only and thus help guide
treatment strategies more accurately en route to improving
outcome. However, in practice, it is likely that not all data are
available at all time points for such a patient-speciﬁc model. In
this case, one could approximate the missing data sets from
published randomized trials both from controls and from
groups that have been treated with a similar protocol. These
population-based data would yield target ranges for the
computer model to explore numerically which missing data
proﬁle ﬁts best to match the patient’s observed tumor growth
patterns. The result is an ‘ad hoc’ combination of population-
based and patient-speciﬁc methods where, conceivably, one
could determine how much personal information is necessary,
at what time point, to run a sufﬁciently meaningful persona-
lized model. This supports the notion of an in silico informed,
customized management of follow-up diagnostics where
expensive exams are spread sufﬁciently thin without compro-
mising the necessary monitoring of the disease under
treatment. The value proposition, in addition to outcome
improvement (with shortened hospital stay and reduced
productivity loss), is that the cost savings from not having to
collect all data from a speciﬁc patient at all time points, for
many cases, outweigh the steep expenditures of the remaining
population-based approaches, which also would likely enroll
less patients to begin with should the new paradigm gain
ground (in turn, limiting costs even more).
(B) For the time being, target discovery in the pharmaceu-
tical industry is still driven by data from in vitro and in vivo
studies, as well as proprietary or published, yet mostly pooled
clinical data. To be fair, customizing any compound from the
get-go to a particular patient is, at least for the time being,
prohibitively costly and thus a non-viable R&D strategy. It is
here where another related systems biology effort will have
impact: identifying biomarkers that strongly correlate with the
cancer system’s dynamics (Sawyers, 2008), hence robustly
reﬂect grading and thus allow proper staging of the disease.
Using computational modeling (Wang et al, 2008), one could
ﬁrst characterize a patient’s speciﬁc biomarkers (ranging from
critical pathway proteins to phenotypic proﬁles and imaging
patterns) and then compare these ‘cross-scale signatures’ with
those seen in pooled data from conventional clinical practice
or from a trial with the candidate drug being applied.
Similarities much like distinct differences could potentially
be correlated with the average outcome observed and thus
exploitedbyproactivelyadjustingthetreatmentregimeninthe
particularcaseathandintheinterestofoptimizingtherapeutic
outcome. In the process, these personalized, biomarker–out-
come relationship data can be properly ITwarehoused and the
resulting databases can be mined for designing future, more
focused trials and to improve such biomarker-based, patient-
speciﬁc ‘consulting’ in going forward.
These examples are by no means intended to be exhaustive
and any combination of these and related scenarios is
conceivable. They are merely meant to demonstrate that a
merger between the two paradigms, brokered by computa-
tional systems medicine, can facilitate the breakthrough of
personalization and add value to population-based ap-
proaches, without having to abandon conventional methods
and techniques in clinics and pharmaceutical industry
altogether. Of course, there are many challenges involved in
making all this happen. Technical obstacles reach from yet
limited scalability of in silico models and necessary standardi-
zations of input data across platforms (Kuo et al, 2006), to
advanced workﬂow design and implementation (Deisboeck
et al, 2007), and data safety and conﬁdentiality measures
(Lunshof et al, 2008). Although any one of these challenges is
formidable, they present intriguing opportunities for innova-
tion,certainlyworthpursuing given thepromisepersonalizing
medicine holds for patients and health-care industry alike.
Conclusions
Owing to an aging baby boomer generation, the US Census
Bureau projects the age group of 65 years and older to increase
from 38.7 million US residents in 2008 to 88.5 million by 2050
(http://www.census2010.gov/Press-Release/www/releases/
archives/population/012496.html). Demands on an already
stretched health-care system will be staggering and calls for a
more innovative, and ultimately more effective management
of R&D in industry and academic medicine will almost
certainly become louder. The status quo strategy in medical
practice is as simple as it now appears to be intrinsically
ﬂawed: carefully assess a patient’s symptoms to diagnose his
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that is based on the assumption that most interpersonal
characteristics are rather inconsequential for treatment out-
come. However, most diseases such as cancer are distinctively
heterogeneous,in itself and acrossthe population and as such,
these characteristics should matter for prediction and real
outcome per se. That is not to say that population-based
medicinewillceaseto playanimportant albeitchanging, more
supportive role; conﬁrming that a majority of patients respond
favorably to a particular treatment, with what is believed to be
acceptable side effects, remains critical information in asses-
sing the averaged risk–beneﬁt of any new treatment for the
population at large. However, even if by these standards a new
drug has been deemed advantageous, we must understand
why it works in most and why it fails in some, a process that
will inevitably lead toward higher data speciﬁcity. Diagnosing
a disease in a particular patient to an ever greater level of
granularity and then tuning treatment to precisely this
information, case-by-case, is the central idea behind persona-
lizing medicine. As detailed above, and despite all technical
challenges involved, there is good reason for integrating
population and personalized medicine in going forward, not
the least of it to control an otherwise prohibitive increase in
costs. In coming off age, computational systems medicine
holds great promise to support and eventually even guide this
effort, and thus to help facilitate this important paradigm shift
in the health-care industry.
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